A protocol schedule is just a defined pattern of when doses occur. Defining it up front is what makes tracking, reminders, and level modelling possible — an undefined schedule cannot be reminded about or plotted.

In plain terms: decide the *when* first, and everything else has something to measure against.

Frequency follows half-life

The single biggest driver of dosing frequency is half-life — how long it takes for half a dose to clear. A compound that is mostly gone in hours appears on frequent research schedules; one that persists for days appears on infrequent ones. The reason is steady-state: frequency is chosen so that levels accumulate into a workable range and stay there, rather than spiking and crashing.

This is why GLP-1 medications are weekly in the literature (very long half-life) while short peptides appear on daily schedules. The pattern is a consequence of the pharmacokinetics, not an arbitrary choice.

In plain terms: fast-clearing compounds need topping up often; slow-clearing ones do not.

Phases

Some protocols are described in phases:

  • A ramp — a lower-intensity opening stretch.
  • A steady period — the main body of the schedule.
  • A taper — winding down at the end.

A schedule that captures phases is more informative than a flat "every day forever," because it reflects how levels actually change across the protocol.

Why a defined schedule matters for tracking

  • Reminders need a defined pattern to fire against.
  • Adherence can only be measured against an expected schedule.
  • Level curves require knowing when doses are *supposed* to happen, not just when they did.
Zyra Labs lets you define a schedule — including recurring patterns and phases — then tracks adherence against it and reminds you when the next dose is due, turning the schedule from an idea into something the app can act on.

Once defined, the schedule feeds everything in how to track a protocol. Note the framing: this explains the *concept* of how schedules relate to pharmacokinetics. What any individual's schedule should be is a clinical question, not something a tracking method decides.